News
9h
TipRanks on MSNAbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment
Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study to ...
9h
TipRanks on MSNAbbVie’s Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa: A Potential Game Changer
Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...
The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...
The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.
2d
Pharmaceutical Technology on MSNAbbVie expands North Chicago API production with $195m investment
AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...
AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...
AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $212.70 today based on a price of $204.94 for ABBV at the time of writing.
AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...
AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast citing strong sales of its newer immunology drugs Skyrizi and Rinvoq.
Over the past five years, ABBV has experienced a negative one-day return following its earnings announcements in 65% of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results